吡格列酮对肥胖小鼠血清抵抗素的影响及其对肾脏的作用

目的:观察肥胖小鼠血清抵抗素的水平及其对肾脏的影响，以及吡格列酮对抵抗素的调节作用。方法:肥胖小鼠随机分为模型组（OB组，n=8）、治疗组（PI组,n=8）；同周龄普通小鼠为正常对照组（NC组,n=8）。PI组给予吡格列酮灌胃，NC组与OB组以等量生理盐水灌胃，12周后测体质量、24 h尿微量白蛋白（ 24 h-mALB）、空腹血糖及血清胰岛素、抵抗素，计算胰岛素抵抗指数；分离腹腔内脂肪并称重，计算脂体比（内脏脂肪质量/体质量）；摘取右肾，光镜下观察肾脏病理变化,测量肾小球直径。结果:OB组脂体比、24 h-mALB、血清抵抗素、胰岛素抵抗指数较NC组明显增加(P<0.05)；PI组与OB组相比上述指标明显下降(P<0.05)；OB组24 h-mALB与脂体比、抵抗素及胰岛素抵抗指数成正相关（r₁=0.789，P<0.05；r₂=0.722, P<0.05;r₃=0.896, P<0.05），抵抗素与脂体比、24 h-mALB及胰岛素抵抗指数成正相关（r₄=0.792，P<0.05；r₅=0.722, P<0.05;r₆=0.762, P<0.05）。结论:肥胖小鼠血清抵抗素明显升高，抵抗素可以通过增加胰岛素抵抗而加重肾脏病理改变及蛋白尿，吡格列酮可以减轻上述改变。

Effect of pioglitazone on serum resistin and kidney in obesity mice

Objective:To observe the serum resistin level obese mice and its effects on kidney,and to study the effect of pioglitazone on resistin. Methods: The obese mice were randomly divided into model group (OB group,n=8), the treatment group (PI group,n=8); and normal control group (NC group,n=8). PI group was given pioglitazone gavage while NC group and the OB group were given saline gavage. Twelve-week post-test body weight, 24 h-mALB, fasting blood glucose and serum insulin, resistin, insulin resistance index were measured; intraperitoneal fat was seperated and weighed to calculate body fat ratio (visceral fat mass / body mass); the right kidney was collected, and kidney pathological changes were observed under light microscope. Glomerular diameter was measured. Results: The Body fat ratio, 24 h-mALB, serum resistin, insulin resistance index in OB group were significantly higher than those in NC group(P<0.05); The levels of the indicators decreased after pioglitazone treatment (P<0.05). Correlation analysis showed that in OB group the 24 h-mALB was positively correlated with body fat ratio, resistin and insulin resistance index （r₁=0.789，P<0.05；r₂=0.722, P<0.05;r₃=0.896, P<0.05）and the resistin levels were positively correlated with body fat ratio, 24h-mALB and insulin resistance index（r₄=0.792，P<0.05；r₅=0.722, P<0.05;r₆=0.762, P<0.05）. Conclusion: Resistin can deteriorate the pathological changes of kidney and increase proteinuria; pioglitazone can reverse these changes.